Market Research Logo

Diabetic Gastroparesis - Pipeline Review, H2 2015

Diabetic Gastroparesis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Diabetic Gastroparesis - Pipeline Review, H2 2015’, provides an overview of the Diabetic Gastroparesis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Gastroparesis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis Overview
Therapeutics Development
Pipeline Products for Diabetic Gastroparesis - Overview
Pipeline Products for Diabetic Gastroparesis - Comparative Analysis
Diabetic Gastroparesis - Therapeutics under Development by Companies
Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes
Diabetic Gastroparesis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Gastroparesis - Products under Development by Companies
Diabetic Gastroparesis - Products under Investigation by Universities/Institutes
Diabetic Gastroparesis - Companies Involved in Therapeutics Development
Cempra, Inc.
Evoke Pharma, Inc.
GlaxoSmithKline Plc
Ironwood Pharmaceuticals, Inc.
Rhythm Pharmaceuticals
Shire Plc
Diabetic Gastroparesis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
camicinal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IW-9179 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metoclopramide hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target nNOS for Diabetic Gastroparesis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
velusetrag hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Gastroparesis - Recent Pipeline Updates
Diabetic Gastroparesis - Dormant Projects
Diabetic Gastroparesis - Discontinued Products
Diabetic Gastroparesis - Product Development Milestones
Featured News & Press Releases
Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001
Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis
May 13, 2015: Ironwood Presents Gastrointestinal Disease Research On IW-9179 at Digestive Disease Week 2015
Apr 14, 2015: Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001
Apr 09, 2015: Evoke Pharma Granted European Union Formulation Patent for EVK-001
Apr 08, 2015: Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
Feb 02, 2015: Evoke Pharma Outlines Progress on Clinical Program
Dec 09, 2014: Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis
Dec 02, 2014: Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study
Sep 09, 2014: Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Gastroparesis, H2 2015
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Diabetic Gastroparesis - Pipeline by Cempra, Inc., H2 2015
Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2015
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2015
Diabetic Gastroparesis - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2015
Diabetic Gastroparesis - Pipeline by Rhythm Pharmaceuticals, H2 2015
Diabetic Gastroparesis - Pipeline by Shire Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Diabetic Gastroparesis Therapeutics - Recent Pipeline Updates, H2 2015
Diabetic Gastroparesis - Dormant Projects, H2 2015
Diabetic Gastroparesis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Diabetic Gastroparesis, H2 2015
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report